From: Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome
Model 1: linear regression analysis with change in GGT as the dependent variable and the following as independent variables in separate analyses | ||||
---|---|---|---|---|
Ā | n | Co-efficient | 95% C.I. | p-value |
Gender (male) | 116 | ā21.04 | ā37..03- ā5.06 | 0.010 |
Pre-TC | 115 | ā3.28 | ā6.18- ā0.38 | 0.027 |
Pre-TG | 116 | ā1.08 | ā2.03- ā0.14 | 0.025 |
Pre fibrate GGT | 116 | ā0.47 | ā0.56- ā0.38 | <0.001 |
Pre fibrate ALT | 114 | ā0.28 | ā0.51- ā0.05 | 0.0180 |
Treatment duration | 117 | 19.7 | 1.35-38.0 | 0.036 |
change in HDL-C | 98 | ā33.79 | ā57.19- ā10.38 | 0.005 |
Model 2: multiple regression analysis with change in GGT as the dependent variable and the following as independent variables in a single analysis. | ||||
Ā | n | Co-efficient | 95% C.I. | p-value |
Gender (male) | 96 (r2 = 0.52) | ā5.47 | ā18.77-7.83 | 0.42 |
Pre-TC | 0.48 | ā3.81-4.77 | 0.83 | |
Pre-TG | ā1.43 | ā3.77-0.91 | 0.23 | |
Pre fibrate GGT | ā0.44 | ā0.56- ā0.31 | <0.001 | |
Pre fibrate ALT | 0.07 | ā0.12-0.26 | 0.48 | |
Treatment duration | 12.5 | 1.86-26.9 | 0.087 | |
change in HDL-C | ā24.61 | ā55.42-6.22 | 0.12 |